Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,792 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer.
Kanai M, Matsumoto S, Nishimura T, Shimada Y, Watanabe G, Kitano T, Misawa A, Ishiguro H, Yoshikawa K, Yanagihara K, Teramukai S, Mitsumori M, Chiba T, Sakai Y, Fukushima M. Kanai M, et al. Among authors: matsumoto s. Int J Clin Oncol. 2007 Jun;12(3):224-7. doi: 10.1007/s10147-007-0666-x. Epub 2007 Jun 27. Int J Clin Oncol. 2007. PMID: 17566847
Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.
Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, Niimi M, Teramukai S, Takahashi R, Mori Y, Kitano T, Ishiguro H, Yanagihara K, Chiba T, Fukushima M, Matsuda F. Kanai M, et al. Among authors: matsumoto s. Cancer Epidemiol. 2010 Apr;34(2):189-93. doi: 10.1016/j.canep.2010.02.008. Epub 2010 Mar 21. Cancer Epidemiol. 2010. PMID: 20308030 Free article.
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, Aggarwal BB. Kanai M, et al. Among authors: matsumoto s. Cancer Chemother Pharmacol. 2011 Jul;68(1):157-64. doi: 10.1007/s00280-010-1470-2. Epub 2010 Sep 22. Cancer Chemother Pharmacol. 2011. PMID: 20859741 Free article. Clinical Trial.
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers.
Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H, Chiba T. Kanai M, et al. Among authors: matsumoto s. Cancer Chemother Pharmacol. 2012 Jan;69(1):65-70. doi: 10.1007/s00280-011-1673-1. Epub 2011 May 21. Cancer Chemother Pharmacol. 2012. PMID: 21603867 Free article. Clinical Trial.
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H. Kanai M, et al. Among authors: matsumoto s. Cancer Chemother Pharmacol. 2013 Jun;71(6):1521-30. doi: 10.1007/s00280-013-2151-8. Epub 2013 Mar 30. Cancer Chemother Pharmacol. 2013. PMID: 23543271 Free article. Clinical Trial.
5,792 results